Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Novo Nordisk Says FDA Approves To Update Victoza Product Label

RELATED NEWS
Trade NVO now with 

Novo Nordisk A/S (NVO: Quote) said Friday that the US Food and Drug Administration has approved to update the product label for Victoza to include data showing superior blood sugar control and weight reduction when compared to Januvia. The update also includes data showing the safety and efficacy of adding basal insulin to Victoza and metformin for the treatment of adults with type 2 diabetes.

The label update is based on data from two large, randomized, open-label studies in adults with type 2 diabetes.

"The data from these studies further demonstrate the strong clinical profile and the value of Victoza in the treatment of type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

Click here to receive FREE breaking news email alerts for Novo Nordisk A/S and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After showing a notable move to the upside in early trading on Tuesday, stocks showed a substantial downturn over the course of the session. Concerns about the impact of new sanctions against Russia weighed on the markets. A day after lawmakers announced an agreement on compromise legislation to reform the Veterans Affairs Department, the Senate voted unanimously Tuesday to confirm a new head of the scandal-plagued department. Looking to increase pressure on Congress, the White House released a report on Tuesday warning of the economic costs of delaying action to address climate change.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.